0.94
-10.95%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $336,600
- Last close × shares
- Volume
- 135.8k
- Shares, 20 Nov 2026
About SeaStar Medical Holding
From its filings with the US Securities and Exchange Commission
SeaStar Medical Holding is based in Denver, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ICU. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $1.2m and a net loss of $12.2m. At that date it held total assets of $14.2m and shareholders' equity of $10.4m.
We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device (“SCD”) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.
We received Food and Drug Administration (“FDA”) approval on February 21, 2024, under a Humanitarian Device Exemption (“HDE”) for our pediatric SCD therapy. It is the only FDA approved product for use in pediatric patients with acute kidney injury (“AKI”) due to sepsis or a septic condition requiring kidney replacement therapy. We shipped our first commercial pediatric SCD (“QUELIMMUNE”) in July 2024. In addition, we are currently conducting a pivotal clinical trial, also referred to as "NEUTRALIZE-AKI" to assess the safety and efficacy of the SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy (“CRRT”). We are also conducting a feasibility study of the SCD therapy in adult patients with Cardiorenal Syndrome ("CRS") awaiting left ventricular assist device ("LVAD") implantation.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Latest on SeaStar Medical Holding
Our reporting
- SeaStar Medical Holding falls 3.06% in Tuesday's session
- SeaStar Medical Holding falls 3.03% in Friday's session
- SeaStar Medical Holding rises 2.02% in Tuesday's session
- SeaStar Medical Holding rises 2.49% in Monday's session
- SeaStar Medical Holding falls 15.44% in Friday's session
- SeaStar Medical Holding rises 3.93% in Wednesday's session
Next results
Due on 24 Mar 2027. Analysts expect earnings of -0.89 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is SeaStar Medical Holding's ticker?
SeaStar Medical Holding trades as ICU on its US listing, under ISIN US81256L3024.
What was SeaStar Medical Holding's last closing price?
0.94 on 20 Nov 2026. The figure is in USD and is never converted.
When does SeaStar Medical Holding next report results?
Results are expected on 11 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.